Sun Pharma to Test Pancreatitis Drug Nafamostat for COVID-19

Sun Pharma has received approval from India to conduct a clinical trial of nafamostat mesilate as a potential COVID-19 treatment.

In early in vitro studies, nafamostat was able suppress a protein that the virus uses to enter human lung cells. It was also shown to inhibit the virus at very low concentrations.

The Indian drugmaker is manufacturing the active pharmaceutical ingredient and the finished product of nafamostat.